GlassScriptPhysician profile
Isaias D Paja
NPI 1518997709
$6,227.17
in general payments reported to CMS, 2019-2025
29 companies · $850 in 2025
The $850 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $845 · 2021: $1,443 · 2022: $1,281 · 2023: $756 · 2024: $681 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,114.66 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $697.92 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $540.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $512.95 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $430.67 | 2022-2025 | |
| Amgen INC. | $385.37 | 2022-2025 | Otezla, Enbrel, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.39 | 2019-2023 | Jardiance |
| Abbvie INC. | $362.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $307.52 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $267.56 | 2019-2024 | Wegovy |
| Gilead Sciences, INC. | $239.19 | 2021-2025 | |
| Dexcom, INC. | $233.65 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $119.27 | 2024-2025 | Daybue |
| Vanda Pharmaceuticals INC. | $90.72 | 2019-2021 | |
| Hologic Sales and Service, LLC | $69.80 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $68.78 | 2023 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $67.35 | 2019-2021 | |
| Organon LLC | $51.86 | 2021-2022 | |
| Allergan, INC. | $49.88 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.62 | 2022 | |
| Roche Diagnostics Corporation | $36.55 | 2020 | |
| Cipher Pharmaceuticals US LLC | $28.61 | 2025 | Natroba, Spinosad |
| Linus Health, INC. | $27.69 | 2022 | |
| Strongbridge US INC. | $20.17 | 2020 | |
| Amarin Pharma, INC. | $18.32 | 2020 | |
| Lundbeck LLC | $14.49 | 2025 | Vyepti |
| Exact Sciences Corporation | $14.12 | 2025 | Cologuard Collection Kit |
| Optinose US, INC. | $14.11 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaias Paja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.